<DOC>
	<DOCNO>NCT01071200</DOCNO>
	<brief_summary>The present study design investigate , hyporesponder subject , require previous assisted reproductive technology ( ART ) cycle follicle stimulate hormone ( FSH ) &gt; 3500 International Unit ( IU ) , possibility decrease recombinant human luteinizing hormone ( r-hLH ) supplementation , FSH amount per oocytes retrieve mean time improve overall cycle outcome .</brief_summary>
	<brief_title>Study Evaluate Addition r-hLH ( Luveris® ) FSH From Day 8 Ovarian Stimulation Able Decrease Total FSH Dose Improve Cycle Outcome Infertile Women Undergoing ART , Who Required High FSH Dose Previous Cycle</brief_title>
	<detailed_description>Recombinant human follicle stimulate hormone ( r-hFSH ) , totally lack LH activity , widely use induce multiple follicle development woman pituitary desensitization , order submit treatment assist reproduction technique ( ART ) . Clinical experience hypogonadotropic-hypogonadic woman suggest FSH alone sufficient induce follicle development , LH play significant part final follicle maturation , estrogen synthesis optimal endometrium growth . This phase III , multicentre , randomize , open-label comparative study evaluate addition r-hLH ( Luveris ) 2:1 ratio FSH day 8 ovarian stimulation able decrease total FSH dose improve cycle outcome 250 infertile woman undergo ART , require high FSH dose previous cycle ( ≥ 3500 IU ) . Subjects met inclusion criterion , achieve pituitary desensitization start controlled ovarian hyperstimulation ( COH ) treatment FSH , stimulation day 8 ( S8 ) receive identification number allocate one two follow arm : Arm : FSH + r-hLH ( 2:1 ratio FSH : r-hLH ) , Arm : FSH alone . Treatment Luveris commence day 8 ( S8 ) continue injection hCG cancellation treatment cycle . Monitoring stimulation , FSH dose escalation , criterion injection hCG , ovum pick , embryo transfer pregnancy confirmation take place accord standard management practice . The in-vitro fertilization ( IVF ) intracytosolic sperm injection ( ICSI ) procedure , include luteal phase support , perform accord centre ' normal procedure . The subject follow treatment outcome ( menstruation pregnancy ) record . The delivery outcome pregnant subject record Case Report Form ( CRF ) . Information delivery outcome pregnancy collect . Information adverse event collect study period . OBJECTIVES The primary objective study : To determine whether addition r-hLH ( Luveris ) day 8 ovarian stimulation reduces FSH dose need obtain/retrieve oocyte . The secondary objective study : - To determine whether addition Luveris FSH day 8 ovarian stimulation improve cycle outcome base secondary endpoint - To determine safety Luveris indication</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Premenopausal infertile woman , age 18 40 year inclusive , wish conceive Regular , spontaneous menstrual cycle 2535 day Body mass index ( BMI ) ≤ 28 FSH ≤ 10 IU/L ( follicular phase , day 25 ) Prolactin ( PRL ) within normal range Evidence ovary ultrasound scan Women undergo IVFEmbryo Transfer ( ET ) ICSI , regulate Gonadotropin release hormone analogue ( GnRHa ) ( daily dose ) control ovarian hyperstimulation ( COH ) FSH Washout &gt; 90 day last dose clomiphene gonadotrophin , ongoing COH cycle Only one previous IVFET ICSI cycle ( last 9 month precede ongoing COH cycle ) result hyporesponse properly document ( 6 12 oocyte total FSH dose ≥ 4000 IU ) Negative pregnancy hCG test ( urine blood sample ) ongoing COH cycle Willing able comply protocol duration study Written inform consent apply procedure relate study protocol , part routine medical care , understand consent may withdraw subject time , without prejudice future medical care Oligo/Anovulatory cycle ( World Health Organization [ WHO ] I II ) Male partner azoospermia ( assess within last 12 month ) Follicular phase ( day 25 ) FSH &gt; 10 IU/L even observe medical history Abnormal cervical cytology ( assess within last 12 month ) History unexplained gynecologic hemorrhage Any contraindication pregnancy Known allergy gonadotrophin Any clinically important systemic disease ( e.g . insulindependent diabetes mellitus , epilepsy , serious migraine , intermittent purpura , hepatic , renal cardiovascular disease , serious corticoiddependent asthma ) constitute contraindication gonadotropin use Any medical condition , accord investigator 's judgement , may affect absorption , distribution , metabolism excretion drug . In case doubt , inclusion subject question discuss Medical Responsible Serono Known Human Immunodeficiency Virus ( HIV ) positivity Any substance abuse history drug alcohol abuse within past 5 year Prior inclusion present study simultaneous inclusion clinical study another drug Refusal inability comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Reproductive Techniques , Assisted</keyword>
	<keyword>Recombinant human follicle stimulate hormone ( r-hFSH )</keyword>
	<keyword>Recombinant leutinizing hormone ( r-hLH )</keyword>
</DOC>